The toxic effects of pathogenic ataxin-3 variants in a yeast cellular model

PLoS ONE

Volumn 10, Issue 6, 2015, Pages

  Bonanomi, Marcella ^a   Visentin, Cristina ^a   Invernizzi, Gaetano ^a,b   Tortora, Paolo ^a   Regonesi, Maria Elena ^a  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ATAXIN 3; FUNGAL PROTEIN; GUANIDINE; POLYGLUTAMINE; PRION PROTEIN; REACTIVE OXYGEN METABOLITE; ANTIOXIDANT; CHAPERONE; DODECYL SULFATE SODIUM; HEAT SHOCK PROTEIN; HSP104 PROTEIN, S CEREVISIAE; MUTANT PROTEIN; PROPIDIUM IODIDE; PROTEIN AGGREGATE; SACCHAROMYCES CEREVISIAE PROTEIN;

ARTICLE; CELL DEATH; CELL GROWTH; CELL MEMBRANE; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVITY; FUNGAL STRAIN; GROWTH INHIBITION; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PROTEIN AGGREGATION; PROTEIN EXPRESSION; SACCHAROMYCES CEREVISIAE; SPINOCEREBELLAR ATAXIA TYPE 3; SPINOCEREBELLAR DEGENERATION; SURVIVAL RATE; WILD TYPE; APOPTOSIS; BIOLOGICAL MODEL; DRUG EFFECTS; ENZYMOLOGY; GROWTH, DEVELOPMENT AND AGING; HUMAN; METABOLISM; SOLUBILITY;

EUKARYOTA; SACCHAROMYCES CEREVISIAE;

ANTIOXIDANTS; APOPTOSIS; ATAXIN-3; GUANIDINE; HEAT-SHOCK PROTEINS; HUMANS; MODELS, BIOLOGICAL; MOLECULAR CHAPERONES; MUTANT PROTEINS; OXIDATIVE STRESS; PROPIDIUM; PROTEIN AGGREGATES; SACCHAROMYCES CEREVISIAE; SACCHAROMYCES CEREVISIAE PROTEINS; SODIUM DODECYL SULFATE; SOLUBILITY;

EID: 84935462298     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0129727     Document Type: Article

References (67)

1. Gatchel JR, Zoghbi HY. Diseases of unstable repeat expansion: mechanisms and common principles. Nat Rev Genet. 2005; 6: 743-755. doi: 10.1038/nrg1691 PMID: 16205714
2. Orr HT, Zoghbi HY. Trinucleotide repeat disorders. Annu Rev Neurosci. 2007; 30: 575-621. doi: 10.1146/annurev.neuro.29.051605.113042 PMID: 17417937
3. Zoghbi HY, Orr HT. Glutamine repeats and neurodegeneration. Annu Rev Neurosci. 2000; 23: 217-247. doi: 10.1146/annurev.neuro.23.1.217 PMID: 10845064
4. Duennwald ML. Polyglutamine misfolding in yeast: toxic and protective aggregation. Prion. 2011; 5: 285-290. doi: 10.4161/pri.18071 PMID: 22052348
5. Zuccato C, Ciammola A, Rigamonti D, Leavitt BR, Goffredo D, Conti L, et al. Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science. 2001; 293: 493-498. doi: 10.1126/science.1059581 PMID: 11408619
6. Zuccato C, Tartari M, Crotti A, Goffredo D, Valenza M, Conti L, et al. Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes. Nat Genet. 2003; 35: 76-83. doi: 10.1038/ng1219 PMID: 12881722
7. Ranum LP, Lundgren JK, Schut LJ, Ahrens MJ, Perlman S, Aita J, et al. Spinocerebellar ataxia type 1 and Machado-Joseph disease: incidence of CAG expansions among adult-onset ataxia patients from 311 families with dominant, recessive, or sporadic ataxia. Am J Hum Genet. 1995; 57: 603-608. PMID: 7668288
8. Riess O, Rüb U, Pastore A, Bauer P, Schöls L. SCA3: neurological features, pathogenesis and animal models. Cerebellum Lond Engl. 2008; 7: 125-137. doi: 10.1007/s12311-008-0013-4
9. Kawaguchi Y, Okamoto T, Taniwaki M, Aizawa M, Inoue M, Katayama S, et al. CAG expansions in a novel gene for Machado-Joseph disease at chromosome 14q32.1. Nat Genet. 1994; 8: 221-228. doi: 10.1038/ng1194-221 PMID: 7874163
10. Trottier Y, Cancel G, An-Gourfinkel I, Lutz Y, Weber C, Brice A, et al. Heterogeneous intracellular localization and expression of ataxin-3. Neurobiol Dis. 1998; 5: 335-347. doi: 10.1006/nbdi.1998.0208 PMID: 10069576
11. Masino L, Musi V, Menon RP, Fusi P, Kelly G, Frenkiel TA, et al. Domain architecture of the polyglutamine protein ataxin-3: a globular domain followed by a flexible tail. FEBS Lett. 2003; 549: 21-25. PMID: 12914917
12. Burnett B, Li F, Pittman RN. The polyglutamine neurodegenerative protein ataxin-3 binds polyubiquitylated proteins and has ubiquitin protease activity. Hum Mol Genet. 2003; 12: 3195-3205. doi: 10.1093/hmg/ddg344 PMID: 14559776
13. Bevivino AE, Loll PJ. An expanded glutamine repeat destabilizes native ataxin-3 structure and mediates formation of parallel beta-fibrils. Proc Natl Acad Sci U S A. 2001; 98: 11955-11960. doi: 10.1073/pnas.211305198 PMID: 11572942
14. Chow MKM, Paulson HL, Bottomley SP. Destabilization of a non-pathological variant of ataxin-3 results in fibrillogenesis via a partially folded intermediate: a model for misfolding in polyglutamine disease. J Mol Biol. 2004; 335: 333-341. PMID: 14659761
15. Williams AJ, Paulson HL. Polyglutamine neurodegeneration: protein misfolding revisited. Trends Neurosci. 2008; 31: 521-528. doi: 10.1016/j.tins.2008.07.004 PMID: 18778858
16. Uversky VN. Mysterious oligomerization of the amyloidogenic proteins. FEBS J. 2010; 277: 2940-2953. doi: 10.1111/j.1742-4658.2010.07721.x PMID: 20546306
17. Campioni S, Mannini B, Zampagni M, Pensalfini A, Parrini C, Evangelisti E, et al. A causative link between the structure of aberrant protein oligomers and their toxicity. Nat Chem Biol. 2010; 6: 140-147. doi: 10.1038/nchembio.283 PMID: 20081829
18. Bucciantini M, Giannoni E, Chiti F, Baroni F, Formigli L, Zurdo J, et al. Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature. 2002; 416: 507-511. doi: 10.1038/416507a PMID: 11932737
19. Lajoie P, Snapp EL. Formation and toxicity of soluble polyglutamine oligomers in living cells. PloS One. 2010; 5: e15245. doi: 10.1371/journal.pone.0015245 PMID: 21209946
20. Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science. 2003; 300: 486-489. doi: 10.1126/science.1079469 PMID: 12702875
21. Demuro A, Mina E, Kayed R, Milton SC, Parker I, Glabe CG. Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers. J Biol Chem. 2005; 280: 17294-17300. doi: 10.1074/jbc.M500997200 PMID: 15722360
22. Kayed R, Sokolov Y, Edmonds B, McIntire TM, Milton SC, Hall JE, et al. Permeabilization of lipid bilayers is a common conformation-dependent activity of soluble amyloid oligomers in protein misfolding diseases. J Biol Chem. 2004; 279: 46363-46366. doi: 10.1074/jbc.C400260200 PMID: 15385542
23. Schaffar G, Breuer P, Boteva R, Behrends C, Tzvetkov N, Strippel N, et al. Cellular toxicity of polyglutamine expansion proteins: mechanism of transcription factor deactivation. Mol Cell. 2004; 15: 95-105. doi: 10.1016/j.molcel.2004.06.029 PMID: 15225551
24. Khurana V, Lindquist S. Modelling neurodegeneration in Saccharomyces cerevisiae: why cook with baker's yeast? Nat Rev Neurosci. 2010; 11: 436-449. doi: 10.1038/nrn2809 PMID: 20424620
25. Duennwald ML. Yeast as a platform to explore polyglutamine toxicity and aggregation. Methods Mol Biol Clifton NJ. 2013; 1017: 153-161. doi: 10.1007/978-1-62703-438-8-11 PMID: 23719914
26. Braun RJ, Büttner S, Ring J, Kroemer G, Madeo F. Nervous yeast: modeling neurotoxic cell death. Trends Biochem Sci. 2010; 35: 135-144. doi: 10.1016/j.tibs.2009.10.005 PMID: 19926288
27. Porzoor A, Macreadie IG. Application of yeast to study the tau and amyloid-β abnormalities of Alzheimer's disease. J Alzheimers Dis JAD. 2013; 35: 217-225. doi: 10.3233/JAD-122035 PMID: 23396350
28. Cooper AA, Gitler AD, Cashikar A, Haynes CM, Hill KJ, Bhullar B, et al. Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. Science. 2006; 313: 324-328. doi: 10.1126/science.1129462 PMID: 16794039
29. Gitler AD, Chesi A, Geddie ML, Strathearn KE, Hamamichi S, Hill KJ, et al. Alpha-synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicity. Nat Genet. 2009; 41: 308-315. doi: 10.1038/ng.300 PMID: 19182805
30. Johnson BS, McCaffery JM, Lindquist S, Gitler AD. A yeast TDP-43 proteinopathy model: Exploring the molecular determinants of TDP-43 aggregation and cellular toxicity. Proc Natl Acad Sci U S A. 2008; 105: 6439-6444. doi: 10.1073/pnas.0802082105 PMID: 18434538
31. Johnson BS, Snead D, Lee JJ, McCaffery JM, Shorter J, Gitler AD. TDP-43 is intrinsically aggregationprone, and amyotrophic lateral sclerosis-linked mutations accelerate aggregation and increase toxicity. J Biol Chem. 2009; 284: 20329-20339. doi: 10.1074/jbc.M109.010264 PMID: 19465477
32. Meriin AB, Zhang X, He X, Newnam GP, Chernoff YO, Sherman MY. Huntington toxicity in yeast model depends on polyglutamine aggregation mediated by a prion-like protein Rnq1. J Cell Biol. 2002; 157: 997-1004. doi: 10.1083/jcb.200112104 PMID: 12058016
33. Duennwald ML, Jagadish S, Muchowski PJ, Lindquist S. Flanking sequences profoundly alter polyglutamine toxicity in yeast. Proc Natl Acad Sci U S A. 2006; 103: 11045-11050. doi: 10.1073/pnas.0604547103 PMID: 16832050
34. Duennwald ML, Lindquist S. Impaired ERAD and ER stress are early and specific events in polyglutamine toxicity. Genes Dev. 2008; 22: 3308-3319. doi: 10.1101/gad.1673408 PMID: 19015277
35. Macedo-Ribeiro S, Cortes L, Maciel P, Carvalho AL. Nucleocytoplasmic shuttling activity of ataxin-3. PloS One. 2009; 4: e5834. doi: 10.1371/journal.pone.0005834 PMID: 19503814
36. Matos CA, de Macedo-Ribeiro S, Carvalho AL. Polyglutamine diseases: the special case of ataxin-3 and Machado-Joseph disease. Prog Neurobiol. 2011; 95: 26-48. doi: 10.1016/j.pneurobio.2011.06.007 PMID: 21740957
37. Invernizzi G, Aprile FA, Natalello A, Ghisleni A, Penco A, Relini A, et al. The relationship between aggregation and toxicity of polyglutamine-containing ataxin-3 in the intracellular environment of Escherichia coli. PloS One. 2012; 7: e51890. doi: 10.1371/journal.pone.0051890 PMID: 23251648
38. Krobitsch S, Lindquist S. Aggregation of huntingtin in yeast varies with the length of the polyglutamine expansion and the expression of chaperone proteins. Proc Natl Acad Sci U S A. 2000; 97: 1589-1594. PMID: 10677504
39. Gietz D, Jean A St, Woods RA, Schiestl RH. Improved method for high efficiency transformation of intact yeast cells. Nucleic Acids Res. 1992; 20: 1425. PMID: 1561104
40. Alberti S, Halfmann R, Lindquist S. Biochemical, cell biological, and genetic assays to analyze amyloid and prion aggregation in yeast. Methods Enzymol. 2010; 470: 709-734. doi: 10.1016/S0076-6879(10)70030-6 PMID: 20946833
41. Natalello A, Frana AM, Relini A, Apicella A, Invernizzi G, Casari C, et al. A major role for side-chain polyglutamine hydrogen bonding in irreversible ataxin-3 aggregation. PloS One. 2011; 6: e18789. doi: 10.1371/journal.pone.0018789 PMID: 21533208
42. Shehi E, Fusi P, Secundo F, Pozzuolo S, Bairati A, Tortora P. Temperature-dependent, irreversible formation of amyloid fibrils by a soluble human ataxin-3 carrying a moderately expanded polyglutamine stretch (Q36). Biochemistry. 2003; 42: 14626-14632. doi: 10.1021/bi0352825 PMID: 14661975
43. Kayed R, Head E, Sarsoza F, Saing T, Cotman CW, Necula M, et al. Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. Mol Neurodegener. 2007; 2: 18. doi: 10.1186/1750-1326-2-18 PMID: 17897471
44. Teparić R, Stuparević I, Mrsa V. Increased mortality of Saccharomyces cerevisiae cell wall protein mutants. Microbiol Read Engl. 2004; 150: 3145-3150. doi: 10.1099/mic.0.27296-0 PMID: 15470095
45. Boyne AF, Ellman GL. A methodology for analysis of tissue sulfhydryl components. Anal Biochem. 1972; 46: 639-653. PMID: 4623507
46. Shangari N, O'Brien PJ. Catalase activity assays. Curr Protoc Toxicol Editor Board Mahin Maines Ed - Chief Al. 2006; Chapter 7: Unit 7.7.1-15. doi: 10.1002/0471140856.tx0707s27
47. McCord JM, Fridovich I. Superoxide dismutase. An enzymic function for erythrocuprein (hemocuprein). J Biol Chem. 1969; 244: 6049-6055. PMID: 5389100
48. Ellisdon AM, Thomas B, Bottomley SP. The two-stage pathway of ataxin-3 fibrillogenesis involves a polyglutamine-independent step. J Biol Chem. 2006; 281: 16888-16896. doi: 10.1074/jbc.M601470200 PMID: 16624810
49. Bonanomi M, Natalello A, Visentin C, Pastori V, Penco A, Cornelli G, et al. Epigallocatechin-3-gallate and tetracycline differently affect ataxin-3 fibrillogenesis and reduce toxicity in spinocerebellar ataxia type 3 model. Hum Mol Genet. 2014; 23: 6542-6552. doi: 10.1093/hmg/ddu373 PMID: 25030034
50. Chernoff YO, Lindquist SL, Ono B, Inge-Vechtomov SG, Liebman SW. Role of the chaperone protein Hsp104 in propagation of the yeast prion-like factor [psi+]. Science. 1995; 268: 880-884. PMID: 7754373
51. Cushman-Nick M, Bonini NM, Shorter J. Hsp104 suppresses polyglutamine-induced degeneration post onset in a drosophila MJD/SCA3 model. PLoS Genet. 2013; 9: e1003781. doi: 10.1371/journal.pgen.1003781 PMID: 24039611
52. Osherovich LZ, Weissman JS. Multiple Gln/Asn-rich prion domains confer susceptibility to induction of the yeast [PSI(+)] prion. Cell. 2001; 106: 183-194. PMID: 11511346
53. Giannattasio S, Atlante A, Antonacci L, Guaragnella N, Lattanzio P, Passarella S, et al. Cytochrome c is released from coupled mitochondria of yeast en route to acetic acid-induced programmed cell death and can work as an electron donor and a ROS scavenger. FEBS Lett. 2008; 582: 1519-1525. doi: 10.1016/j.febslet.2008.03.048 PMID: 18396162
54. Miller-Fleming L, Giorgini F, Outeiro TF. Yeast as a model for studying human neurodegenerative disorders. Biotechnol J. 2008; 3: 325-338. doi: 10.1002/biot.200700217 PMID: 18228539
55. Heinicke S, Livstone MS, Lu C, Oughtred R, Kang F, Angiuoli SV, et al. The Princeton Protein Orthology Database (P-POD): a comparative genomics analysis tool for biologists. PloS One. 2007; 2: e766. doi: 10.1371/journal.pone.0000766 PMID: 17712414
56. Hübener J, Vauti F, Funke C, Wolburg H, Ye Y, Schmidt T, et al. N-terminal ataxin-3 causes neurological symptoms with inclusions, endoplasmic reticulum stress and ribosomal dislocation. Brain J Neurol. 2011; 134: 1925-1942. doi: 10.1093/brain/awr118 PMID: 21653538
57. Lashuel HA, Hartley D, Petre BM, Walz T, Lansbury PT Jr. Neurodegenerative disease: amyloid pores from pathogenic mutations. Nature. 2002; 418: 291. doi: 10.1038/418291a PMID: 12124614
58. Harman D. Free Radical Theory of Aging: An Update. Ann N Y Acad Sci. 2006; 1067: 10-21. doi: 10.1196/annals.1354.003 PMID: 16803965
59. Denoth Lippuner A, Julou T, Barral Y. Budding yeast as a model organism to study the effects of age. FEMS Microbiol Rev. 2014; 38: 300-325. doi: 10.1111/1574-6976.12060 PMID: 24484434
60. Yu Y-C, Kuo C-L, Cheng W-L, Liu C-S, Hsieh M. Decreased antioxidant enzyme activity and increased mitochondrial DNA damage in cellular models of Machado-Joseph disease. J Neurosci Res. 2009; 87: 1884-1891. doi: 10.1002/jnr.22011 PMID: 19185026
61. Pacheco LS, da Silveira AF, Trott A, Houenou LJ, Algarve TD, Belló C, et al. Association between Machado-Joseph disease and oxidative stress biomarkers. Mutat Res. 2013; 757: 99-103. doi: 10.1016/j.mrgentox.2013.06.023 PMID: 23994570
62. McLaurin J, Chakrabartty A. Characterization of the interactions of Alzheimer beta-amyloid peptides with phospholipid membranes. Eur J Biochem FEBS. 1997; 245: 355-363. PMID: 9151964
63. Lindgren M, Hammarström P. Amyloid oligomers: spectroscopic characterization of amyloidogenic protein states. FEBS J. 2010; 277: 1380-1388. doi: 10.1111/j.1742-4658.2010.07571.x PMID: 20148961
64. Jayasinghe SA, Langen R. Membrane interaction of islet amyloid polypeptide. Biochim Biophys Acta. 2007; 1768: 2002-2009. doi: 10.1016/j.bbamem.2007.01.022 PMID: 17349968
65. Pellistri F, Bucciantini M, Invernizzi G, Gatta E, Penco A, Frana AM, et al. Different ataxin-3 amyloid aggregates induce intracellular Ca(2+) deregulation by different mechanisms in cerebellar granule cells. Biochim Biophys Acta. 2013; 1833: 3155-3165. doi: 10.1016/j.bbamcr.2013.08.019 PMID: 24035922
66. Richter C. Biophysical consequences of lipid peroxidation in membranes. Chem Phys Lipids. 1987; 44: 175-189. PMID: 3311416
67. Butterfield DA, Castegna A, Lauderback CM, Drake J. Evidence that amyloid beta-peptide-induced lipid peroxidation and its sequelae in Alzheimer's disease brain contribute to neuronal death. Neurobiol Aging. 2002; 23: 655-664. PMID: 12392766